Myriad Genetics' Q1 Revenues Up 8 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sales of women's health products helped drive Myriad Genetics' total revenues up 8 percent in the company's fiscal first quarter for 2011, but short of analysts' estimates.

For the three months ended Sept. 30, total revenues increased to $91.9 million, compared to $85.1 million a year ago, helped by an 18 percent jump in revenues related to woman's health products to $25.8 million from $21.8 million, the company reported after the close of market on Tuesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.